Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Aberrant activation of the Mitogen-Activated Protein Kinase (MAPK) pathway fuels cell proliferation in various cancers.
• BRAF and MEK kinase inhibitors are established treatments for BRAF-mutant melanoma, yet therapeutic resistance is a significant clinical challenge, often driven by enhanced ERK1/2 signaling.

Purpose of the Study:

• To develop novel ERK1/2 inhibitors using a fragment-based approach.
• To generate compounds that modulate ERK1/2 activity and overcome resistance mechanisms in BRAF-mutant cancers.

Main Methods:

• Fragment-based screening using X-ray crystallography and biophysical techniques.
• Structure-guided drug design and optimization.
• In vitro assays to assess kinase inhibition and cellular proliferation.
• In vivo studies using BRAF-mutant xenograft models.

Main Results:

• Identification of highly potent and kinome-selective ERK1/2 inhibitors.
• The lead compound effectively suppresses phosphorylated RSK (pRSK) and phosphorylated ERK1/2 (pERK) levels in BRAF-mutant cells.
• Demonstrated inhibition of cancer cell proliferation at nanomolar concentrations.
• Achieved tumor regression in preclinical xenograft models upon oral administration.

Conclusions:

• Fragment-based drug discovery yielded potent ERK1/2 inhibitors with a novel mechanism of action.
• These inhibitors target key signaling nodes in the MAPK pathway, offering a potential strategy to overcome resistance.
• The lead compound shows therapeutic promise for BRAF-mutant cancers and warrants further clinical development.